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Abstract 
Gastric cancer (GC) is the third leading cause of cancer-related deaths. More than 80% of the 
diagnosis was made at the advanced stages of the disease, highlighting the urgent demand for novel 
biomarkers that can be used for early detection. Recently, a number of studies suggest that cir-
culating microRNAs (miRNAs) could be potential biomarkers for GC diagnosis. Cancer-related 
circulating miRNAs, as well as tissue miRNAs, provide a hopeful prospect of detecting GC at early 
stages, and the prospective participation of miRNAs in biomarker development will enhance the 
sensitivity and specificity of diagnostic tests for GC. As miRNAs in blood are stable, their potential 
value as diagnostic biomarkers in GC has been explored over the past few years. However, due to 
the inconsistent or sometimes conflicting reports, large-scale prospective studies are needed to 
validate their potential applicability in GC diagnosis. This review summarizes the current devel-
opment about potential miRNA biomarkers for GC diagnosis and the obstacles hindering their 
clinical usage. 
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Introduction 
Gastric cancer (GC) is the third most common 
cause of cancer-related mortality worldwide, and has 
a particularly high incidence in Asian countries in-
cluding China and Japan. Although the incidence of 
gastric cancer has been reduced in certain developed 
countries over the past few decades, there are still 
over 1 million newly diagnosed cases and 850,000 
deaths globally each year. More than 70% of the cases 
occurs in developing countries, with 50% occur in 
Eastern Asia [1].  
Due to the absence of specific early symptoms, 
most GCs are diagnosed at advanced stages with no 
effective treatment. As the prognosis for GC patients 
differs depending on the disease stage at the time of 
diagnosis, early detection of GC is crucial. Endoscopic 
biopsy is the best way to find GC before presenting 
clinic symptoms, however, few patients would like to 
undergo endoscopy due to the potential side effects, 
including aspiration pneumonia, bleeding, and per-
foration. Hence, there is an urge need for the discov-
ery of non-invasive early detection biomarkers for GC 
patients. 
Nowadays, several serum tumor markers have 
been used in clinic for several years, such as 
α-fetoprotein (AFP), carcinoembryonic antigen (CEA) 
and carbohydrate antigens 125 and 19-9(CA 125 and 
CA 19-9). However, none of these markers are specific 
or sensitive in GC, especially in the early stage. Even 
though the combined use of these tumor markers 
improves the sensitivity to some extent for the ad-
vanced GC, these markers yield inconsistent results 
when used for early GC detection [2]. Therefore, 
identifying novel sensitive biomarkers for early GC 
diagnosis have become a hot research topic world-
wide [3, 4, 5].  
Despite extensive studies, the exact molecular 
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mechanisms of GC are still poorly understood. GC 
development is a complex, multi-step process in-
volving deregulation of several oncogenic pathways. 
These oncogenic signaling pathways can be activated 
by some genetic and epigenetic alterations, such as the 
aberrant gene methylation, histone modifications and 
microRNA regulation. Increasing evidence indicates 
that GC is largely governed by complex interactions 
between multiple pro- and anti-oncogenic signaling 
pathways [6].  
MiRNAs are small non-coding RNAs, about 
18-24 nucleotides in length that control various bio-
logical processes through binding to the 3’ untrans-
lated region (UTR) of mRNAs, and affecting the sta-
bility and translation of their target genes. miRNAs 
function through miRNA-RNA induced silencing 
complex, which binds to specific mRNA targets via 
base pairing at the 3′-UTR, leading to translational 
repression or degradation of these mRNAs. In addi-
tion, miRNAs have also been shown to target mRNAs 
in the coding region, 5′-UTR as well as promoter re-
gion. This sparked great interests in elucidating the 
dynamic roles of miRNA that may play in the devel-
opment and progression of cancer, and led to the 
rapid expansion of this field [7] [8] [9]. According to 
miRBase Release 21 (June 2014), 2,588 unique mature 
human miRNAs have been identified [5, 6].  
Although the biological function of miRNAs has 
yet to be fully understood, miRNA analyses indicate 
that a wide range of cancers display significantly dif-
ferential expression profiles compared to normal tis-
sues [10] [11] [12] [13] [14] [15]. Since miRNAs are 
gene expression regulators, identification of aberrant 
tissue-specific miRNA expression in certain cancer 
may provide potential new biomarkers for clinical 
diagnosis, evaluation of prognosis, and choice of 
treatment [16] [17] [18] [19] [20]. Previous studies have 
revealed dozens of miRNAs that play important roles 
in gastric tumorigenesis, and might be potential bi-
omarkers [21] [22] [23] [24] [25] [26]. As a potential 
biomarker that could be applied in clinical use, the 
selected cancer-associated markers, such as miRNA 
biomarkers, should be easy to detect, ideally from 
body fluids, such as blood. Thus researchers have 
devoted to identifying the sensitive miRNA markers 
in the blood for GC patients [27] [28] [29] [30] [31] [32]. 
Circulating miRNAs remain stable after incuba-
tion at room temperature for up to 24h or after up to 
eight cycles of freeze-thawing [32]. Their stability and 
easily testable length (about 22bp) make miRNAs 
suitable for being cancer biomarkers. Fortunately, 
several circulating miRNAs have been identified, 
which are significantly changed in their expression in 
GC patients compared to that of normal population 
[33] [34] [35].  
Up-regulated circulating miRNAs in GC  
In 2010, Tsujiura et al first reported the expres-
sion of a group of circulating miRNAs (miR-17-5p, 
miR-21, miR-106a, miR-106b and let-7a) were signifi-
cantly aberrant in plasma of GC patients [36]. 
MiR-17-5p, miR-21, miR-106a and miR-106b expres-
sion were significantly upregulated whereas let-7a 
was downregulated in GC patients. Although the 
study only included 69 GC patients and 30 healthy 
volunteers, it indicated that detection of circulating 
miRNAs might provide new complementary tumor 
markers for GC patients.  
Manuel Valladares-Ayerbes et al [37] analyzed 
the microarray expression profiles of the miR-200 
family in 160 paired samples of non-tumor gastric 
mucosae and GC downloaded from ArrayExpress. 
Then they selected miR-200c for validation, and found 
a significantly increased blood miR-200c expression 
level compared to normal controls by qRT-PCR. Alt-
hough the specificity was 100% but =sensitivity was 
only about 65%. Increased miR-200c expression in 
blood were significantly associated with lymph node 
metastases and overall survival, but not with other 
clinical or pathological characteristics. These data 
suggest miR-200c has the potential to be a circulating 
diagnostic and prognostic biomarker.  
In an E-cadherin / p53 double conditional 
knockout (DCKO) mouse model that recapitulates 
human diffuse-type GC (DGC) morphologically and 
molecularly, Rotkrua and his colleagues [38] demon-
strated that DCKO mouse and human GCs are very 
similar in miRNA expression patterns. Among the 
reported 11 highly expressed serum miRNAs in hu-
man GC, four miRNAs, miR-103, miR-107, miR-194, 
and miR-210, were verified upregulated in sera of 
DCKO mice with both early- and advanced-stage 
DGC. Furthermore, the elevation of miR-103 and 
miR-194 occurred during the entire progression from 
the non-cancer status to the advanced-stage, implying 
they could be used as biomarkers in diagnosing the 
DGC stage. In addition, a high level of miR-210 may 
be a diagnostic biomarker for other cancers, including 
diffuse large B-cell lymphoma, pancreatic cancer and 
breast cancer. 
There are several other reported up-regulated 
miRNAs that could be used as potential circulating 
biomarkers. For example, Li et al [39] [40] investigated 
the expression of miRNA-199a-3p between 
pre-operative plasma from EGC (early gastric cancer) 
patients and healthy controls; and between 
pre-operative and post-operative plasma using 
qRT-PCR. They found that the expression of plasma 
miRNA-199a-3p in EGC patients was significantly 
higher than that of healthy controls and gastric pre-
cancerous diseases (GPD) patients. In addition, the 
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expression of miRNA-199a-3p in plasma was signifi-
cantly decreased in the post-operative patients. The 
AUC of miRNA-199a-3p expression in plasma for 
EGC diagnosis was much higher than that of com-
bined tumor markers. Therefore, plasma miR-
NA-199a-3p may serve as a prognostic biomarker for 
EGC. Furthermore, the expression of miRNA-199a-3p, 
miR-221, miR-106b and miR-20a are significantly el-
evated in plasma of GC patients. 
Fu Z et al [29] analyzed the level of circulating 
miR-222 in plasma of GC patients using qRT-PCR in 
114 GC patients, compared to 36 chronic atrophic 
gastritis (CAG) patients and 56 healthy controls. The 
results showed that the expression of circulating 
miR-222 in plasma was significantly upregulated in 
GC compared with either CAG or healthy controls. 
And its expression level was significantly correlated 
with clinical stages and lymph nodes metastasis. The 
ROC curve analysis revealed that miR-222 had con-
siderable diagnostic accuracy, yielded an AUC of 
0.850 with 66.1 % sensitivity and 88.3 % specificity in 
discriminating GC from healthy controls. Moreover, 
Kaplan-Meier analysis demonstrated a correlation 
between increased circulating miR-222 level and re-
duced disease-free survival and overall survival. 
These findings suggested that circulating miR-222 in 
plasma might be a potential and useful non-invasive 
biomarker for the early detection and prognosis of 
GC. 
MiR-106b-25 has been studied in several cancers. 
Zhang R et al [41] tested miR-106b-25 expression in 40 
post-operative and 20 pre-operative plasma samples 
of GC patients and explored the correlation between 
MiR-106b-25 and related clinical pathological factors. 
The expression of miR-106b-25 cluster in plasma was 
significantly correlated with tumor size, pathological 
type and TNM stage in GC patients. What's more, the 
three members of miR-106b-25 cluster expressed con-
sistently at a high level both in tissue and plasma. 
Considering the relationship between three miRNAs 
and some clinical pathological factors, it was implied 
that miR-106b-25 could be the potential tumor bi-
omarker for diagnosis and prognosis for GC patients. 
In another study, circulating miR-122 and -192 
expression levels were analyzed in GC patients with 
qRT-PCR [42]. They found that plasma miR-122 ex-
pression was significantly decreased while miR-192 
was increased in GC/DM samples compared to nor-
mal or benign controls. The similar expression pattern 
of these two miRNAs was observed in patients with 
post-distant metastases compared to those with 
pre-distant metastases. . Dysregulation of miR-122 
expression but not miR-192 expression in plasma was 
associated with more favorable prognosis for GC. This 
suggests that that evaluation of circulating miR-122 
and miR-192 expression levels could potentially help 
early detection of DM in GC.  
Tsujiura M et al [43] hypothesized that miR-18a, 
which is a member of miR-17-92 cluster and has been 
reported as highly expressed in GC tissues, could be 
used as a novel plasma biomarker in GC patients. The 
study showed that miR-18a expression in both biopsy 
tissues and plasma was significantly higher in GC 
patients than in healthy controls, with AUC value of 
0.8059. The plasma miR-18a levels were significantly 
reduced in post-operative plasma compared to that of 
preoperative samples. In a miR-18a overexpressing 
cell line, the miR-18a concentration in cultured me-
dium was increased, suggesting that miRNA-18a 
might be released from cancer cells into the sur-
rounding environment. Therefore, circulating 
miR-18a could be a useful biomarker for screening GC 
and monitoring tumor dynamics. 
There were many other circulating miRNAs re-
portedly increased in GC, such as miR-21 [44] [45] [46] 
[47] [48] [49] [50] [51], miR-221 [52], miR-378 [53], 
miR-451 and miR-486 [54]. Several studies found that 
miR-421 was overexpressed in GC [55] [56] [57], and 
the positive detection rate of miR-421 is higher than 
that of serum CEA. Since the serum concentration of 
miR-421 has higher sensitivity and specificity than 
CEA [58], miR-421 may serve as an efficient early di-
agnostic biomarker. Along with the in-depth study 
about the circulating miRNAs associated with GC, 
more miRNAs would be found to have the potential 
of being diagnosis biomarkers in GC.  
Down-regulated circulating miRNAs in 
GC 
Besides the up-regulated miRNA, there were 
also down-regulated miRNA in GC.  
Multiple groups reported and validated that 
miR-375 was down-regulated in GC [59] [60, 61] [62]. 
miR-375 was significantly down-regulated in distal 
gastric adenocarcinoma tissues as well as in serum 
[63]. At a normalized cutoff of 0.218, miR-375 yielded 
a receiver operating [62] characteristic (ROC) area 
under the curve (AUC) of 0.835 with a specificity of 
80% and a sensitivity of 85%, in the discrimination of 
distal gastric adenocarcinoma from control tissues, 
while the level of miR-31 was significantly lower [64] 
[65]. Another study found that miR-195-5p was sig-
nificantly down-regulated in GC, indicating 
miR-195-5p may serve as a novel tumor suppressor 
miRNA involving gastric carcinogenesis [66].  
There were over 20 down-regulated circulating 
miRNAs reported till today, yet their clinical utility 
needs to be validated [67]. 
 Journal of Cancer 2015, Vol. 6 
 
http://www.jcancer.org 
1209 
Table 1. Up-regulated circulating miRNA in GC  
Author miRNA Samples Methods Proportion Usage 
Tsujiura [36] miR-17-5P 
miR-21 
miR-106a 
miR-106b 
69 GC patients, 30 healthy 
volunteer 
qRT-PCR  miR-17-5p(P=0.006, ),miR-21 (P=0.05), miR-106a 
(P=0.008) and miR-106b (P<0.001, AUC=0.721) 
higher in GC, let- 7a (P=0.002) lower, ratio of 
miR-106a/let-7a AUC= 0.879 
Early diagnosis 
Manuel Val-
ladares-Ayerbe
s [37] 
miR-200c 67 blood samples (52 stage I-IV 
GC patients and 15 
controls 
qRT-PCR AUC-ROC was 0.715(P=0.012), Sensitivity 65.4%, 
specificity 100%, accurate rate 73.1% 
Diagnostic, prognos-
tic biomarker 
Rotkrua [38] miR-103, -107, - 
194, -210 
DCKO rat model, 5 
DGC-bearing mice vs 5 con-
trols 
TaqMan q 
RT–PCR, miRNA 
microarrays 
miR-103, miR-107, miR-194, miR-210 (P=0.045, 
0.004, 0.004 and 0.030) was higher in DCKO 
mouse sera 
Early diagnosis of 
DGC 
Rotkrua [39,40] miR-199a-3p 30 EGC patients and 70 con-
trols 
miRNA microar-
ray, qRT-PCR  
AUC for EGC 0.818,sensitivity 76%, specificity 
74%, and accuracy 75%,P<0.001 
Diagnostic biomarker 
for EGC 
Fu Z [29] miR-222 114 GC patients , 36 CAG 
patients, 56 healthy controls 
qRT-PCR AUC 0.850, sensitivity 66.1 %, specificity 88.3 %  Early detection and 
prognosis of GC 
Zhang R [41] miR-106b-25 
clus-
ter(miR-106b, 
-93, -25) 
40 post-operative and 20 
pre-operative plasma samples 
TaqMan qRT–PCR Change fold were 2.51(miR106b), 2.32(miR-93), 
2.10(miR-25)respectively, correlated with tumor 
size, bomman type and TNM stage(P<0.05) 
Diagnosis and prog-
nosis biomarker 
Chen Q [42] miR-192 12 pairs of samples qRT-PCR AUC for plasma miR-192 was 0.732(95% CI 
0.623-0.841,P<0.01) 
Early diagnosis 
Tsujiura M [43] miR-18a 104 GC patients, 65 healthy 
volunteers 
qRT-PCR Higher miR-18a in GC than controls, 
P<0.0001,ROC value 0.8059 
Screening GC and 
monitoring tumor 
dynamics 
Wu J [58] miR-421 90 GC patients and 90 controls qRT-PCR Higher sensitivity and specificity than CEA and 
CA-125 in GC diagnosis  
Early diagnosis 
Song J [48] miR-21 103 GC patients qRT-PCR Increased level of miR-21 associated with tumor 
size and pT stages(r=0.2633,P=0.0072) 
Indicator for tumor 
burden in GC pa-
tients, biomarker for 
therapy 
Table 2. Down-regulated circulating miRNA in GC 
Author miRNA Samples Methods Proportion Usage 
Chen Q[42] miR-122 12 pairs of blood 
samples 
qRT-PCR AUC for plasma miR-122 was 
0.808, 95% CI 0.712-0.905,P<0.01 
miR-122 down-regulated in GC, higher 
miR-122 may indicate a favorable prognosis 
Zhang WH[68] miR-375  Microarray, 
qRT-PCR 
miR-375 ROC 0.835, specificity 
80%, sensitivity 85% 
Biomarker for distal GC 
Gorur A[71] miR-195-5p 20 blood samples 
from GC patients 
and 190 volunteers 
q RT-PCR miR-195-5p down-regulated 13.3 
fold, P<0.05 
miR-195-5p was a tumor suppressor miRNA 
and may contribute to gastric carcinogenesis 
 
 
Difficulties in the application of circu-
lating miRNAs as GC diagnostic bi-
omarkers 
1. Suitable internal reference genes  
The prospective studies about circulating miR-
NAs suggested a bright future for the development of 
non-invasive biomarkers for GC molecular diagnosis. 
However, the accurate identification of miRNA-based 
biomarkers has been a significant challenge and is still 
difficult in clinical settings. Measurement of circulat-
ing miRNAs may be influenced by a number of fac-
tors, including amount of starting materials, methods 
of sample collection, RNA extraction, etc. . Among the 
reported potential circulating miRNAs, some of them 
were detected in serum, others in plasma. One of the 
meta-analyses suggested that plasma-based miRNA 
assay reached a higher accuracy compared to se-
rum-based one for GC [68]. Meanwhile, technical 
challenges exist in measuring circulating miRNA. 
Because of the relatively low expression of RNA 
isoforms in serum and plasma, conventional methods 
of spectrophotometry are not reliable to control for 
total amount of RNA extracted from samples; and the 
high concentration of miRNAs in blood cells can eas-
ily confound results if these are not removed carefully 
and/or cellular lysis is not prevented [69].  
In a research on internal control small RNA U6 
expression, Xiang M et al [70] found that the expres-
sion level of U6 was gradually decreased after 1, 2, 
and 4 cycles of freezing and thawing. It is reasoned to 
doubt that the expression of miRNA markers may not 
be stable and could be fluctuant under different cycles 
of freezing and thawing. More thorough research and 
standard procedure of sample collection should be 
established before these novel biomarkers being used 
in practice. 
Furthermore, age and sex may be confounding 
variables when miRNAs were measured from blood 
samples. Meder B et al [71] explored the impact of age 
and sex on miRNAs in a cohort of 109 physiologically 
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unaffected individuals whose blood miRNAs was 
characterized by microarray technology. They also 
investigated an independent cohort from a different 
institution consisting of 58 physiologically unaffected 
individuals with similar mean age, but with a smaller 
age distribution. The samples were measured with 
high-throughput sequencing. They detected 318 
miRNAs that were significantly correlated with age 
and, after adjustment for multiple testing, 35 of them 
remained statistically significant. Regarding sex, 144 
miRNAs showed significant dysregulation; however, 
no miRNA remained significant after adjustment for 
multiple testing. In the high-throughput datasets, 
they observed a smaller number of significant associ-
ations, mainly as an effect of the smaller cohort size 
and age distribution. They concluded that age distri-
bution of individuals recruited for case-control stud-
ies needs to be carefully considered, whereas sex may 
be less confounding. Thus the possible influence of 
age or sex should be considered when the expression 
of circulating miRNAs is being assessed. 
The main method of miRNA detection was re-
al-time quantitative Polymerase Chain Reaction 
(qPCR). This effective technology could significantly 
amplify the tiny content of miRNAs to an easily de-
tectable level. There are numerous challenges to 
achieve sufficient sensitivity and specificity in the 
measuring circulating miRNAs, particularly in se-
lecting appropriate normalization controls. There is 
however currently no agreement on this issue, which 
makes it impossible to compare the results from dif-
ferent labs or platforms. Therefore, it is essential to 
develop an effective and uniformed normalization 
strategy in evaluating circulating miRNA expression 
levels. One of the popular and relatively accurate 
strategies is to use a stable reference gene or a set of 
gene signatures (s) to evaluate circulating miRNA 
expression. Otherwise the data may not be reliable. 
One example is to use the same amount of the starting 
total RNA, however, due to the low yield of total RNA 
from serum or plasma, it is hard to measure the RNA 
yield and quality accurately with the available meth-
ods [72]. 
Despite the most common controls, U6 and 
miR-16 are used as internal control for miRNA quan-
tification, Xiang M et al [70] found large fluctuations 
in U6 expression from their microarray-based serum 
miRNA profiling on a number of cancer patients and 
normal controls. They also demonstrated that the ex-
pression of U6, miR-16 and miR-24 in serum was 
subjected to different freeze-thaw cycles. Therefore, 
U6 may not be an ideal internal control for circulating 
miRNAs. 
 In order to identify stable controls for circulat-
ing miRNA quantification, a global circulating miR-
NA profiling study was performed using healthy 
controls, chronic hepatitis B, cirrhosis and a variety of 
cancer patients The most stable controls were selected 
by a number of programs, such as GeNorm, 
NormFinder, and coefficient of variability (CV). Seven 
candidates miRNAs, miR-1225-3p, miR-1228, 
miR-30d, miR-939, miR-940, miR-188-5p, and miR-134 
were identified, and validated by qPCR, along with 
the commonly used four other controls, miR-16, 
miR-223, let-7a, and RNU6B using an independent 
cohort. miR-1228 (CV = 5.4%) turns out to be the most 
stable one among all tested. Interestingly, miR-1228 is 
involved in metabolism-related signal pathways and 
organ morphology by Ingenuity Pathway Analysis 
(IPA), which suggests that miR-1228 may be a 
housekeeping miRNA gene. The stable expression of 
miR-1228 in the blood may qualify it as a promising 
control for circulating microRNAs quantification [73]. 
Another study indicated that miR-93 may be a useful 
internal control for serum miRNA analysis in GC [34].  
Chen X et al. [74] screened and validated the 
reference genes using a strategy by combining the 
Illumina’s sequencing by synthesis (SBS) technology, 
qPCR, literature screening and statistical analysis. . A 
panel of let-7d, let-7g and let-7i was developed as a 
reference set for circulating miRNA normalization, 
and subsequently validated across numerous healthy 
controls and patients, and was demonstrated to be 
statistically better than the commonly used reference 
set, such as U6, RNU44, RNU48 and miR-16. Because 
of the variations of the internal control genes, special 
attention should be paid when comparing the diag-
nostic value of the circulating miRNAs.  
2. High specificity and sensitivity of circulating 
miRNAs  
As ideal diagnostic biomarkers, circulating 
miRNAs should be specific enough to distinguish GC 
from other diseases, and sensitive to be detectable. 
However, most of the reported circulating miRNAs 
with aberrant expression profile in GC were also ob-
served in other cancers. For example, the expression 
of miR-200 family was dysregulated not only in GC 
[75], but also in colorectal carcinoma [76] [77] [78], 
hepatocellular carcinoma [79], anaplastic thyroid 
cancer [80], ovarian cancer [81] [82], breast cancer [83] 
[84], prostate cancer [85], and pancreatic cancer [86]. 
MiR-222 was classified as oncomiR both in GC and 
hepatitis B-related hepatocellular carcinoma [87]. 
Even the contradictory results were found on the 
same miRNA in GC. For example, miR-199a-3p was 
found both up-regulated [40] and down-regulated 
[88] in GC in different studies.  
Since there is no single circulating miRNA that 
could be used to diagnose GC till today, the combina-
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tion of several miRNAs has been presented by some 
researchers. In a meta-analysis research, a total of 107 
studies from 42 articles were included about the po-
tential circulating miRNAs in GC and colorectal can-
cer (CRC). The overall analysis of all GI cancers 
showed that circulating miRNAs have a relatively 
good diagnostic performance. In addition, sin-
gle-miRNA assay displayed a relatively low diagnos-
tic performance, while multiple-miRNA assay signif-
icantly improved the diagnostic accuracy for GC and 
CRC [68]. Therefore, a signature of miRNAs may 
serve as promising biomarkers for the diagnosis of 
GC.  
In another meta-analysis conducting to assess 
the diagnostic value of circulating miRNAs for GC in 
Asian population, the literature search was carried 
out in databases (PubMed, Embase, Web of Science, 
The Cochrane Library, and CNKI) and other sources 
using combinations of keywords relating to GC, 
miRNAs, and diagnosis. The values of sensitivity, 
specificity, positive likelihood ratios (PLR), negative 
likelihood ratios (NLR), and diagnostic odds ratio 
(DOR) reported in individual studies were pooled 
using random-effects models. Potential sources of 
heterogeneity were assessed with subgroup and me-
ta-regression analyses. The summary receiver oper-
ating characteristic (SROC) curve and the AUC were 
used to assess the diagnostic accuracy of miRNAs. 
This meta-analysis included 1,279 patients with GC 
and 954 healthy controls from 20 publications. The 
pooled sensitivity, specificity, PLR, NLR, DOR, and 
AUC were 0.78, 0.80, 4.0, 0.28, 14, and 0.86, respec-
tively. Subgroup analyses showed that early stages (I 
and II) GC were more easily detected than later stag-
es, and that multiple miRNAs assays were more ac-
curate than single miRNA assays [89]. This me-
ta-analysis concluded that miRNAs had a higher di-
agnostic value for GC in early stages (I and II) than in 
late stages, and multiple miRNAs assays had a better 
diagnostic value than single miRNA assays.  
Besides the meta-analysis, a panel of five miR-
NAs (miR-16, miR-25, miR-92a, miR-451 and 
miR-486-5p) seemed to show consistently high level 
expression in GC patients’ plasma [31]. This 5-miRNA 
panel may serve as a potential non-invasive bi-
omarker in early GC detection.  
The combination of miRNA markers could con-
sist of both up-regulated and down-regulated miR-
NAs. For example, overexpressed miR-223, miR-21 
and underexpressed miR-218 in GC patients yield the 
AUC values of 0.9089, 0.7944, and 0.7432, respectively, 
while the combined ROC analysis reveals the highest 
AUC value of 0.9531 in discriminating GC patients 
from healthy controls [44]. This suggests that a cluster 
of miRNAs would be a better diagnostic biomarker 
than single miRNA, with much higher sensitivity, 
specificity, and accuracy.  
Conclusions 
The search for better non-invasive biomarkers 
for the diagnosis of GC has led to the investigation of 
aberrant circulating miRNAs in plasma or serum. The 
expression level of miRNAs could be easily detected 
using qRT-PCR. The studies demonstrated that higher 
sensitivity and specificity can be achieved by circu-
lating miRNAs as compared to other commonly used 
biomarkers. Furthermore, the combination of several 
miRNAs reached higher specificity and sensitivity 
than single miRNA. However, the standard protocol 
of sample treatment and the suitable internal controls 
should be further established to make the detection 
comparable before the miRNA biomarkers being fully 
utilized in clinical practice.  
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